The Arctic AβPP mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated Aβ

Acta Neuropathologica Communications

Volumn 2, Issue 1, 2014, Pages

  Kalimo, Hannu ^b,e   Lalowski, Maciej ^c   Bogdanovic, Nenad ^d   Philipson, Ola ^a   Bird, Thomas D ^f   Nochlin, David ^g   Schellenberg, Gerard D ^h   Brundin, RoseMarie ^a   Olofsson, Tommie ⁱ   Soliymani, Rabah ^c   Baumann, Marc ^c   Wirths, Oliver ^j   Bayer, Thomas A ^j   Nilsson, Lars N G ^a,k   Basun, Hans ^a   Lannfelt, Lars ^a   Ingelsson, Martin ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF TURKU   (Finland)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^g New Jersey Neuroscience Institute   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ Department of Forensic Medicine   (Sweden)

^j UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^k OSLO UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

Arctic A PP mutation; Familial Alzheimer's disease; Hyperphosphorylated tau; Mass spectrometry; Neuronal damage; Topography of A ; Truncation of A ; amyloid peptide

Indexed keywords

EID: 85005773744     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/2051-5960-1-60     Document Type: Article

References (52)

1. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, et al.: A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012, 488: 96-99. 10.1038/nature11283
2. Crook R, Verkkoniemi A, Perez-Tur J, Mehta N, Baker M, Houlden H, Farrer M, Hutton M, Lincoln S, Hardy J, et al.: A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat Med 1998, 4: 452-455. 10.1038/nm0498-452
3. Verkkoniemi A, Kalimo H, Paetau A, Somer M, Iwatsubo T, Hardy J, Haltia M: Variant Alzheimer disease with spastic paraparesis: neuropathological phenotype. J Neuropathol Exp Neurol 2001, 60: 483-492.
4. Shepherd C, McCann H, Halliday GM: Variations in the neuropathology of familial Alzheimer's disease. Acta Neuropathol 2009, 118: 37-52. 10.1007/s00401-009-0521-4
5. Tomidokoro Y, Rostagno A, Neubert TA, Lu Y, Rebeck GW, Frangione B, Greenberg SM, Ghiso J: Iowa variant of familial Alzheimer's disease: accumulation of posttranslationally modified AbetaD23N in parenchymal and cerebrovascular amyloid deposits. Am J Pathol 2010, 176: 1841-1854. 10.2353/ajpath.2010.090636
6. Maat-Schieman M, Roos R, van Duinen S: Hereditary cerebral hemorrhage with amyloidosis-Dutch type. Neuropathology 2005, 25: 288-297. 10.1111/j.1440-1789.2005.00631.x
7. Bugiani O, Giaccone G, Rossi G, Mangieri M, Capobianco R, Morbin M, Mazzoleni G, Cupidi C, Marcon G, Giovagnoli A, et al.: Hereditary cerebral hemorrhage with amyloidosis associated with the E693K mutation of APP. Arch Neurol 2010, 67: 987-995. 10.1001/archneurol.2010.178
8. Miravalle L, Tokuda T, Chiarle R, Giaccone G, Bugiani O, Tagliavini F, Frangione B, Ghiso J: Substitutions at codon 22 of Alzheimer's abeta peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells. J Biol Chem 2000, 275: 27110-27116.
9. Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, Kanemitsu H, Takuma H, Kuwano R, Imagawa M, Ataka S, et al.: A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol 2008, 63: 377-387. 10.1002/ana.21321
10. Kamino K, Orr HT, Payami H, Wijsman EM, Alonso ME, Pulst SM, Anderson L, O'Dahl S, Nemens E, White JA, et al.: Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region. Am J Hum Genet 1992, 51: 998-1014.
11. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG, et al.: The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci 2001, 4: 887-893. 10.1038/nn0901-887
12. Stenh C, Englund H, Lord A, Johansson AS, Almeida CG, Gellerfors P, Greengard P, Gouras GK, Lannfelt L, Nilsson LN: Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Ann Neurol 2005, 58: 147-150. 10.1002/ana.20524
13. Scholl M, Wall A, Thordardottir S, Ferreira D, Bogdanovic N, Langstrom B, Almkvist O, Graff C, Nordberg A: Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology 2012, 79: 229-236. 10.1212/WNL.0b013e31825fdf18
14. Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, Ohnishi K, Ishibashi K, Teraoka R, Sakama N, Yamashita T, et al.: A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci 2010, 30: 4845-4856. 10.1523/JNEUROSCI.5825-09.2010
15. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH: Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005, 8: 79-84. 10.1038/nn1372
16. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH: A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440: 352-357. 10.1038/nature04533
17. Basun H, Bogdanovic N, Ingelsson M, Almkvist O, Naslund J, Axelman K, Bird TD, Nochlin D, Schellenberg GD, Wahlund LO, Lannfelt L: Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease. Arch Neurol 2008, 65: 499-505. 10.1001/archneur.65.4.499
18. Philipson O, Lord A, Lalowski M, Soliymani R, Baumann M, Thyberg J, Bogdanovic N, Olofsson T, Tjernberg LO, Ingelsson M, et al.: The Arctic amyloid-beta precursor protein (AbetaPP) mutation results in distinct plaques and accumulation of N- and C-truncated Abeta. Neurobiol Aging 2012,33(1010):e1011-e1013.
19. Lord A, Englund H, Soderberg L, Tucker S, Clausen F, Hillered L, Gordon M, Morgan D, Lannfelt L, Pettersson FE, Nilsson LN: Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. FEBS J 2009, 276: 995-1006. 10.1111/j.1742-4658.2008.06836.x
20. Thal DR, Rub U, Orantes M, Braak H: Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58: 1791-1800. 10.1212/WNL.58.12.1791
21. Aho L, Pikkarainen M, Hiltunen M, Leinonen V, Alafuzoff I: Immunohistochemical visualization of amyloid-beta protein precursor and amyloid-beta in extra- and intracellular compartments in the human brain. J Alzheimers Dis 2010, 20: 1015-1028.
22. Duyckaerts C, Delatour B, Potier MC: Classification and basic pathology of Alzheimer disease. Acta Neuropathol 2009, 118: 5-36. 10.1007/s00401-009-0532-1
23. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, et al.: National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012, 8: 1-13. 10.1016/j.jalz.2011.10.007
24. Hyman BT, Trojanowski JQ: Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 1997, 56: 1095-1097. 10.1097/00005072-199710000-00002
25. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, et al.: National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 2012, 123: 1-11. 10.1007/s00401-011-0910-3
26. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K: Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006, 112: 389-404. 10.1007/s00401-006-0127-z
27. Alafuzoff I, Arzberger T, Al-Sarraj S, Bodi I, Bogdanovic N, Braak H, Bugiani O, Del-Tredici K, Ferrer I, Gelpi E, et al.: Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Brain Pathol 2008, 18: 484-496.
28. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41: 479-486. 10.1212/WNL.41.4.479
29. Weller RO, Subash M, Preston SD, Mazanti I, Carare RO: Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol 2008, 18: 253-266.
30. Koivunen J, Verkkoniemi A, Aalto S, Paetau A, Ahonen JP, Viitanen M, Nagren K, Rokka J, Haaparanta M, Kalimo H, Rinne JO: PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. Brain 2008, 131: 1845-1853. 10.1093/brain/awn107
31. Crick FC, Koch C: What is the function of the claustrum? Philos Trans R Soc Lond B Biol Sci 2005, 360: 1271-1279. 10.1098/rstb.2005.1661
32. Wirths O, Bethge T, Marcello A, Harmeier A, Jawhar S, Lucassen PJ, Multhaup G, Brody DL, Esparza T, Ingelsson M, et al.: Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. J Neural Transm 2010, 117: 85-96. 10.1007/s00702-009-0314-x
33. Atwood CS, Martins RN, Smith MA, Perry G: Senile plaque composition and posttranslational modification of amyloid-beta peptide and associated proteins. Peptides 2002, 23: 1343-1350. 10.1016/S0196-9781(02)00070-0
34. Castano EM, Prelli F, Soto C, Beavis R, Matsubara E, Shoji M, Frangione B: The length of amyloid-beta in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Implications for the role of amyloid-beta 1-42 in Alzheimer's disease. J Biol Chem 1996, 271: 32185-32191. 10.1074/jbc.271.50.32185
35. Cynis H, Scheel E, Saido TC, Schilling S, Demuth HU: Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta. Biochemistry 2008, 47: 7405-7413. 10.1021/bi800250p
36. Miravalle L, Calero M, Takao M, Roher AE, Ghetti B, Vidal R: Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques. Biochemistry 2005, 44: 10810-10821. 10.1021/bi0508237
37. Moro ML, Giaccone G, Lombardi R, Indaco A, Uggetti A, Morbin M, Saccucci S, Di Fede G, Catania M, Walsh DM, et al.: APP mutations in the Abeta coding region are associated with abundant cerebral deposition of Abeta38. Acta Neuropathol 2012, 124: 809-821. 10.1007/s00401-012-1061-x
38. Sahlin C, Lord A, Magnusson K, Englund H, Almeida CG, Greengard P, Nyberg F, Gouras GK, Lannfelt L, Nilsson LN: The Arctic Alzheimer mutation favors intracellular amyloid-beta production by making amyloid precursor protein less available to alpha-secretase. J Neurochem 2007, 101: 854-862. 10.1111/j.1471-4159.2006.04443.x
39. Qahwash I, He W, Tomasselli A, Kletzien RF, Yan R: Processing amyloid precursor protein at the beta-site requires proper orientation to be accessed by BACE1. J Biol Chem 2004, 279: 39010-39016. 10.1074/jbc.M407101200
40. Russo C, Schettini G, Saido TC, Hulette C, Lippa C, Lannfelt L, Ghetti B, Gambetti P, Tabaton M, Teller JK: Presenilin-1 mutations in Alzheimer's disease. Nature 2000, 405: 531-532. 10.1038/35014735
41. Norlin N, Hellberg M, Filippov A, Sousa AA, Grobner G, Leapman RD, Almqvist N, Antzutkin ON: Aggregation and fibril morphology of the Arctic mutation of Alzheimer's Abeta peptide by CD, TEM, STEM and in situ AFM. J Struct Biol 2012, 180: 174-189. 10.1016/j.jsb.2012.06.010
42. Dahlgren KN, Manelli AM, Stine WB Jr, Baker LK, Krafft GA, LaDu MJ: Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 2002, 277: 32046-32053. 10.1074/jbc.M201750200
43. Lashuel HA, Hartley DM, Petre BM, Wall JS, Simon MN, Walz T, Lansbury PT Jr: Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores. J Mol Biol 2003, 332: 795-808. 10.1016/S0022-2836(03)00927-6
44. Paivio A, Jarvet J, Graslund A, Lannfelt L, Westlind-Danielsson A: Unique physicochemical profile of beta-amyloid peptide variant Abeta1-40E22G protofibrils: conceivable neuropathogen in arctic mutant carriers. J Mol Biol 2004, 339: 145-159. 10.1016/j.jmb.2004.03.028
45. Cheng IH, Palop JJ, Esposito LA, Bien-Ly N, Yan F, Mucke L: Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. Nat Med 2004, 10: 1190-1192. 10.1038/nm1123
46. Englund H, Sehlin D, Johansson AS, Nilsson LN, Gellerfors P, Paulie S, Lannfelt L, Pettersson FE: Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J Neurochem 2007, 103: 334-345.
47. Kheterpal I, Lashuel HA, Hartley DM, Walz T, Lansbury PT Jr, Wetzel R: Abeta protofibrils possess a stable core structure resistant to hydrogen exchange. Biochemistry 2003, 42: 14092-14098. 10.1021/bi0357816
48. Kirkitadze MD, Kowalska A: Molecular mechanisms initiating amyloid beta-fibril formation in Alzheimer's disease. Acta Biochim Pol 2005, 52: 417-423.
49. Wirths O, Multhaup G, Bayer TA: A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide-the first step of a fatal cascade. J Neurochem 2004, 91: 513-520. 10.1111/j.1471-4159.2004.02737.x
50. Wirths O, Bayer TA: Intraneuronal Abeta accumulation and neurodegeneration: lessons from transgenic models. Life Sci 2012, 91: 1148-1152. 10.1016/j.lfs.2012.02.001
51. Wirths O, Breyhan H, Cynis H, Schilling S, Demuth HU, Bayer TA: Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol 2009, 118: 487-496. 10.1007/s00401-009-0557-5
52. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R: Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991, 30: 572-580. 10.1002/ana.410300410